Symbols / OGEN
OGEN Chart
About
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Sarasota, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.49M |
| Enterprise Value | -8.07M | Income | -10.90M | Sales | — |
| Book/sh | 2.38 | Cash/sh | 2.74 | Dividend Yield | — |
| Payout | 0.00% | Employees | 3 | IPO | — |
| P/E | 0.02 | Forward P/E | -0.08 | PEG | — |
| P/S | — | P/B | 0.35 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 3.97 |
| Current Ratio | 4.42 | Debt/Eq | 4.02 | LT Debt/Eq | — |
| EPS (ttm) | 48.21 | EPS next Y | -10.80 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2023-05-12 16:00 | ROA | -71.33% |
| ROE | -168.95% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 4.17M |
| Shs Float | 4.07M | Short Float | 12.63% | Short Ratio | 0.62 |
| Short Interest | — | 52W High | 9.60 | 52W Low | 0.61 |
| Beta | 1.11 | Avg Volume | 359.28K | Volume | 117.11K |
| Target Price | — | Recom | None | Prev Close | $0.71 |
| Price | $0.84 | Change | 18.55% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.84
Latest analyst target
3. DCF / Fair value
$-24.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.84
Low
—
High
—
Mean
—
- $OGEN stock is down 9% today. Here's what we see in our data. - Quiver Quantitative hu, 22 Jan 2026 08
- Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants - Yahoo Finance ue, 01 Jul 2025 07
- Oragenics stock tumbles after announcing $20 million preferred stock offering - Investing.com ue, 01 Jul 2025 07
- symbol__ Stock Quote Price and Forecast - CNN hu, 08 Feb 2024 18
- Oragenics Extends At-the-Market Equity Sales Agreement - TipRanks hu, 22 Jan 2026 08
- Oragenics (OGEN) Progresses ONP-002 for Potential $9 Billion Con - GuruFocus Mon, 09 Feb 2026 15
- 12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga Wed, 28 Jan 2026 08
- Oragenics announces reverse stock split to begin June 3 - Investing.com Wed, 28 May 2025 07
- Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split - Yahoo Finance Wed, 28 May 2025 07
- OGEN - Oragenics Latest Stock News & Market Updates - Stock Titan hu, 24 Dec 2020 13
- Why Is Oragenics (OGEN) Stock Down 45% Today? - InvestorPlace Wed, 28 Feb 2024 08
- Alteogen seeks KOSPI transfer, past moves show short-term price peaks - CHOSUNBIZ - Chosunbiz Mon, 10 Nov 2025 08
- What hedge fund moves indicate for Northern Funds Northern Trust 2045 stock - July 2025 Reactions & Accurate Entry/Exit Alerts - mfd.ru Mon, 16 Feb 2026 12
- OGEN Stock Price and Chart — AMEX:OGEN - TradingView Fri, 21 Jul 2017 04
- 7 Short-Squeeze Stocks to Buy Before They Soar - Nasdaq Mon, 30 Jan 2023 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 210 | 198.0 | — | Sale at price 0.94 per share. | TELLING FREDERICK W | Director | — | 2025-12-12 00:00:00 | D |
| 1 | 210 | 198.0 | — | Sale at price 0.94 per share. | TELLING FREDERICK W | Director | — | 2025-12-12 00:00:00 | D |
| 2 | 7044 | 30407.0 | — | Sale at price 4.26 - 4.46 per share. | ODYSSEY HEALTH, INC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-18 00:00:00 | D |
| 3 | 10000 | 43600.0 | — | Sale at price 4.27 - 4.45 per share. | ODYSSEY HEALTH, INC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-16 00:00:00 | D |
| 4 | 5000 | nan | — | — | KOSKI ROBERT C | Director | — | 2024-12-11 00:00:00 | I |
| 5 | 3597 | 1295.0 | — | Sale at price 0.36 per share. | TELLING FREDERICK W | Director | — | 2024-12-06 00:00:00 | D |
| 6 | 66 | 24.0 | — | Sale at price 0.36 per share. | DUNTON ALAN WILLIAM | Director | — | 2024-12-06 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -10.51M | -20.60M | -14.23M | -15.65M |
| TotalUnusualItems | -25.17K | |||
| TotalUnusualItemsExcludingGoodwill | -25.17K | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -10.57M | -20.66M | -14.29M | -15.71M |
| ReconciledDepreciation | 0.00 | 27.39K | 44.67K | 41.24K |
| EBITDA | -10.54M | -20.60M | -14.23M | -15.65M |
| EBIT | -10.54M | -20.63M | -14.27M | -15.70M |
| NetInterestIncome | 16.07K | 179.80K | 120.80K | 60.09K |
| InterestExpense | 29.83K | 30.59K | 15.10K | 15.76K |
| InterestIncome | 45.90K | 210.39K | 135.90K | 75.85K |
| NormalizedIncome | -10.54M | -20.66M | -14.29M | -15.71M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -10.57M | -20.66M | -14.29M | -15.71M |
| TotalExpenses | 10.56M | 20.90M | 14.42M | 15.77M |
| TotalOperatingIncomeAsReported | -10.56M | -20.90M | -14.42M | -15.77M |
| DilutedAverageShares | 220.73K | 74.99K | 66.97K | 64.77K |
| BasicAverageShares | 220.73K | 74.99K | 66.97K | 64.77K |
| DilutedEPS | -48.00 | -275.40 | -213.30 | -242.70 |
| BasicEPS | -48.00 | -275.40 | -213.30 | -242.70 |
| DilutedNIAvailtoComStockholders | -10.57M | -20.66M | -14.29M | -15.71M |
| NetIncomeCommonStockholders | -10.57M | -20.66M | -14.29M | -15.71M |
| NetIncome | -10.57M | -20.66M | -14.29M | -15.71M |
| NetIncomeIncludingNoncontrollingInterests | -10.57M | -20.66M | -14.29M | -15.71M |
| NetIncomeContinuousOperations | -10.57M | -20.66M | -14.29M | -15.71M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -10.57M | -20.66M | -14.29M | -15.71M |
| OtherIncomeExpense | -25.17K | 69.36K | 11.58K | 670.00 |
| OtherNonOperatingIncomeExpenses | 69.36K | 11.58K | 670.00 | |
| GainOnSaleOfSecurity | -25.17K | |||
| NetNonOperatingInterestIncomeExpense | 16.07K | 179.80K | 120.80K | 60.09K |
| InterestExpenseNonOperating | 29.83K | 30.59K | 15.10K | 15.76K |
| InterestIncomeNonOperating | 45.90K | 210.39K | 135.90K | 75.85K |
| OperatingIncome | -10.56M | -20.90M | -14.42M | -15.77M |
| OperatingExpense | 10.56M | 20.90M | 14.42M | 15.77M |
| OtherOperatingExpenses | -37.65K | -131.52K | -86.99K | |
| OtherTaxes | 5.14K | 1.36K | ||
| ResearchAndDevelopment | 4.11M | 15.49M | 10.07M | 10.59M |
| SellingGeneralAndAdministration | 6.44M | 5.45M | 4.48M | 5.27M |
| GeneralAndAdministrativeExpense | 6.44M | 5.45M | 4.48M | 5.27M |
| OtherGandA | 6.44M | 5.45M | 4.48M | 5.27M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 419.00K | 102.69K | 67.49K | 64.66K |
| ShareIssued | 419.00K | 102.69K | 67.49K | 64.66K |
| TotalDebt | 328.53K | 322.51K | 624.53K | 797.21K |
| TangibleBookValue | -211.88K | 1.58M | 11.42M | 23.83M |
| InvestedCapital | 116.64K | 1.89M | 11.68M | 24.13M |
| WorkingCapital | -211.88K | 2.07M | 12.69M | 26.26M |
| NetTangibleAssets | -211.88K | 3.17M | 13.01M | 26.49M |
| CapitalLeaseObligations | 0.00 | 9.81K | 356.89K | 493.79K |
| CommonStockEquity | -211.88K | 1.58M | 11.42M | 23.83M |
| PreferredStockEquity | 1.59M | 1.59M | 2.66M | |
| TotalCapitalization | -211.88K | 3.17M | 13.01M | 26.49M |
| TotalEquityGrossMinorityInterest | -211.88K | 3.17M | 13.01M | 26.49M |
| StockholdersEquity | -211.88K | 3.17M | 13.01M | 26.49M |
| RetainedEarnings | -216.79M | -206.22M | -185.56M | -171.27M |
| AdditionalPaidInCapital | 216.56M | 207.79M | 196.98M | 195.10M |
| CapitalStock | 12.57K | 1.60M | 1.59M | 2.66M |
| CommonStock | 12.57K | 3.08K | 2.02K | 2.00K |
| PreferredStock | 0.00 | 1.59M | 1.59M | 2.66M |
| TotalLiabilitiesNetMinorityInterest | 1.68M | 1.80M | 1.75M | 1.74M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 152.44K | 299.52K |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 152.44K | 299.52K | |
| LongTermCapitalLeaseObligation | 0.00 | 152.44K | 299.52K | |
| CurrentLiabilities | 1.68M | 1.80M | 1.60M | 1.45M |
| CurrentDebtAndCapitalLeaseObligation | 328.53K | 322.51K | 472.09K | 497.69K |
| CurrentCapitalLeaseObligation | 0.00 | 9.81K | 204.45K | 194.27K |
| CurrentDebt | 328.53K | 312.70K | 267.64K | 303.42K |
| CurrentNotesPayable | 328.53K | 312.70K | 267.64K | 303.42K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 8.40K | 7.98K | 33.55K | 57.73K |
| PayablesAndAccruedExpenses | 1.35M | 1.47M | 1.09M | 889.84K |
| CurrentAccruedExpenses | 202.83K | 222.74K | 843.96K | 34.86K |
| Payables | 1.14M | 1.24M | 246.69K | 854.98K |
| AccountsPayable | 1.14M | 1.24M | 246.69K | 854.98K |
| TotalAssets | 1.47M | 4.97M | 14.76M | 28.23M |
| TotalNonCurrentAssets | 0.00 | 1.10M | 468.50K | 523.59K |
| NonCurrentPrepaidAssets | 0.00 | 1.09M | 0.00 | |
| NetPPE | 0.00 | 9.81K | 468.50K | 523.59K |
| AccumulatedDepreciation | 0.00 | -1.36M | -1.63M | |
| GrossPPE | 0.00 | 9.81K | 1.83M | 2.15M |
| Leases | 0.00 | 487.87K | 487.87K | |
| OtherProperties | 9.81K | 1.02M | 1.35M | |
| MachineryFurnitureEquipment | 0.00 | 319.69K | 314.98K | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 1.47M | 3.87M | 14.29M | 27.71M |
| OtherCurrentAssets | 607.67K | 382.27K | 2.86M | 434.70K |
| PrepaidAssets | 2.86M | 434.70K | ||
| Receivables | 0.00 | 6.99K | ||
| OtherReceivables | 6.99K | |||
| CashCashEquivalentsAndShortTermInvestments | 864.84K | 3.48M | 11.43M | 27.27M |
| CashAndCashEquivalents | 864.84K | 3.48M | 11.43M | 27.27M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -8.60M | -8.29M | -15.36M | -13.51M |
| RepurchaseOfCapitalStock | 0.00 | -5.64M | ||
| RepaymentOfDebt | -693.11K | -566.05K | -564.21K | -524.98K |
| IssuanceOfDebt | 0.00 | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 6.67M | 849.93K | 69.29K | 26.68M |
| CapitalExpenditure | -1.00M | -127.52K | -43.88K | |
| InterestPaidSupplementalData | 29.83K | 30.59K | 9.29K | 15.76K |
| EndCashPosition | 864.84K | 3.48M | 11.43M | 27.27M |
| BeginningCashPosition | 3.48M | 11.43M | 27.27M | 17.64M |
| ChangesInCash | -2.62M | -7.94M | -15.84M | 9.63M |
| FinancingCashFlow | 5.98M | 283.88K | -494.92K | 23.14M |
| CashFlowFromContinuingFinancingActivities | 5.98M | 283.88K | -494.92K | 23.14M |
| ProceedsFromStockOptionExercised | 0.00 | 2.62M | ||
| NetPreferredStockIssuance | 0.00 | -5.64M | ||
| PreferredStockPayments | 0.00 | -5.64M | ||
| NetCommonStockIssuance | 6.67M | 849.93K | 69.29K | 26.68M |
| CommonStockIssuance | 6.67M | 849.93K | 69.29K | 26.68M |
| NetIssuancePaymentsOfDebt | -693.11K | -566.05K | -564.21K | -524.98K |
| NetShortTermDebtIssuance | -693.11K | -566.05K | -564.21K | -524.98K |
| ShortTermDebtPayments | -693.11K | -566.05K | -564.21K | -524.98K |
| ShortTermDebtIssuance | 0.00 | 0.00 | 0.00 | |
| InvestingCashFlow | 0.00 | -936.28K | -115.52K | -43.88K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -936.28K | -115.52K | -43.88K |
| NetIntangiblesPurchaseAndSale | 0.00 | -1.00M | 0.00 | |
| PurchaseOfIntangibles | 0.00 | -1.00M | 0.00 | |
| NetPPEPurchaseAndSale | 0.00 | 63.72K | -115.52K | -43.88K |
| SaleOfPPE | 0.00 | 63.72K | 12.00K | 0.00 |
| PurchaseOfPPE | 0.00 | -127.52K | -43.88K | |
| OperatingCashFlow | -8.60M | -7.29M | -15.23M | -13.47M |
| CashFlowFromContinuingOperatingActivities | -8.60M | -7.29M | -15.23M | -13.47M |
| ChangeInWorkingCapital | 1.45M | 2.02M | -1.72M | 512.14K |
| ChangeInOtherCurrentLiabilities | -9.81K | -347.07K | ||
| ChangeInOtherCurrentAssets | 9.81K | 337.63K | 0.00 | |
| ChangeInPayablesAndAccruedExpense | -119.80K | 25.80K | 176.62K | 10.55K |
| ChangeInPrepaidAssets | 1.57M | 2.00M | -1.90M | 508.58K |
| ChangeInReceivables | 0.00 | 6.99K | -6.99K | |
| OtherNonCashItems | 10.27M | |||
| StockBasedCompensation | 516.05K | 1.02M | 742.20K | 1.69M |
| DepreciationAmortizationDepletion | 0.00 | 27.39K | 44.67K | 41.24K |
| DepreciationAndAmortization | 0.00 | 27.39K | 44.67K | 41.24K |
| OperatingGainsLosses | 29.96K | -10.96K | ||
| GainLossOnSaleOfPPE | 0.00 | 29.96K | -10.96K | 0.00 |
| NetIncomeFromContinuingOperations | -10.57M | -20.66M | -14.29M | -15.71M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for OGEN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|